Abstract 12740: Efficacy and Safety of Empagliflozin in Acute Heart Failure: A Systematic Review and Meta-Analysis
Abstract
Introduction:
Acute heart failure (AHF) significantly burdens healthcare systems, leading to hospitalizations, morbidity, and mortality in older adults. Among patients suffering from chronic heart failure, empagliflozin, which is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, has shown positive cardiovascular effects. While several studies have investigated SGLT-2 inhibitor use in hospitalized AHF patients, there is a lack of meta-analysis specifically focused on empagliflozin. To ascertain the efficacy and safety of empagliflozin in AHF, the following systematic review plus meta-analysis was conducted.
Methods:
We comprehensively searched Cochrane, Clinicaltrials.gov, and MEDLINE databases. After title, abstract, and full-text screening, the data discussing relevant safety and efficacy outcomes of empagliflozin were extracted, and a random-effects meta-analysis odds ratio was calculated. We conducted a sensitivity analysis by removing the post-hoc study.
Results:
We retrieved 852 documents after initial database searches, and after the screening, 3 RCTs were included with 824 participants. Empagliflozin significantly reduced the odds of all-cause mortality (OR: 0.47, 95%CI: 0.29-0.78, p=0.004) and cardiovascular death (OR: 0.56, 95%CI: 0.38-0.82, p=0.003) when compared to placebo. Furthermore, empagliflozin demonstrated a lower serious adverse event risk (OR: 0.62, 95% CI: 0.44-0.87, p=0.005) without exacerbating adverse drug effects such as acute kidney injury,…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 824 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.